DARE
Dare Bioscience, Inc. (DARE) 10Y Growth Potential Analysis (2026)
No material changes this month.
Revenue Growth Drivers
No disclosed 5-year revenue, EPS, or FCF CAGR limits evidence of durable compounding versus peers with verified multi-year growth trajectories.
Very high R&D intensity at 160.4% of revenue suggests heavy reinvestment, but peer comparison is weak because spending has not yet translated into scalable revenue.
Negative ROIC of -1.79% indicates capital deployed so far has not produced efficient expansion, reducing confidence in repeatable long-term growth versus profitable peers.
Capex at 33.8% of revenue signals meaningful investment, yet the absence of proven operating leverage implies expansion remains unvalidated relative to scaled peers.
Market Tailwinds
No segmentation or concentration data is provided, so the company’s ability to scale through diversified demand channels cannot be evidenced versus peers.
Negative interest coverage suggests financial strain can absorb growth capacity, leaving less room for sustained reinvestment than stronger peer balance sheets.
The available metrics show funding intensity rather than demand-led expansion, which is weaker than peers with demonstrated recurring revenue momentum.
Without disclosed growth history, market tailwinds remain unproven, so long-term revenue expansion depends more on execution than on verified structural demand.
Scalability Expansion
Negative ROIC and negative interest coverage indicate scaling has not yet produced self-funding economics, unlike peers that compound growth from internal cash generation.
Cash conversion cycle of -92.5 days is operationally efficient, but it has not yet offset weak profitability enough to prove scalable expansion.
Net debt to EBITDA of 0.64x is manageable, yet leverage alone does not create growth capacity without demonstrated earnings conversion.
The current profile looks development-stage rather than scaled, so expansion potential is constrained by unproven monetization relative to established peers.
Constraints Limitations
Negative ROIC is the clearest structural constraint because it shows invested capital has not yet generated durable revenue-producing returns versus peers.
Interest coverage of -55.7x indicates earnings are insufficient to support financing costs, which can limit reinvestment and slow multi-year scaling.
R&D intensity above revenue suggests a high-cost growth model, and peers with lower spend intensity and positive returns have clearer compounding paths.
The lack of disclosed historical growth metrics prevents validation of repeatability, making long-term scalability materially less certain than for reporting peers.
Overall Score
DARE shows heavy reinvestment and some working-capital efficiency, but negative ROIC, negative interest coverage, and missing multi-year growth evidence point to structurally weak compounding capacity versus peers.
Score Driver: Negative ROIC
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Dare Bioscience, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
